The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Dr. Farrukh Awan on Clinical Activity of Entospletinib in Patients with CLL

Farrukh Awan, MBBS
Published Online: 2:39 PM, Mon December 7, 2015


Farrukh T. Awan, MBBS, associate professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University Comprehensive Cancer Center, discusses a phase II trial examining the clinical activity of entospletinib in patients with chronic lymphocytic leukemia (CLL) who were previously treated with a B-cell receptor pathway signaling inhibitor.


Awan says treatment for CLL is rapidly evolving at this time and many patients are being exposed to kinase inhibitor treatments. He adds that when a patient fails a TKI treatment, further treatment is not well-defined. Data from the phase II trial shows that entospletinib is a well-tolerated compand in patients with CLL.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.